Debrief

This case supports concern for CML because the blood pattern combines marked neutrophilic leukocytosis, a broad maturation spectrum, a prominent myelocyte population, and absolute basophilia. BCR::ABL1 detection supplies the defining molecular evidence. The pattern alone does not diagnose CML, determine a transcript, or assign phase. The molecular value alone does not direct treatment.

WHO fifth edition treats CML as chronic or blast phase and replaces accelerated phase with high-risk chronic-phase features. ICC 2022 retains accelerated phase and specifies separate thresholds and cytogenetic criteria. Therefore phase classification is a controlled integrated-classification task using the framework named by the report and full diagnostic data, not an independent CBC, smear, or molecular-monitoring category.

For serial standard-transcript monitoring, the deciding evidence is the documented IS calibration or conversion, transcript identity, reference-gene adequacy, sensitivity, and method comparability. A valid but noncomparable result is released with its limitation and sent to the defined molecular-review pathway rather than deleted or joined to a local trend.